GleamWall
中文EN

PURE PURE BIOSCIENCE, INC.

Miscellaneous Chemical Products · OTC · SEC CIK 1006028 · Fiscal year ends 07/31

Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.3%
TTM net income YoY-3.5%
TTM EPS YoY0.0%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR—

Margins

Gross margin57.3%
Operating margin-90.0%
Net margin-107.3%
FCF margin—
EBITDA margin-89.8%

Returns

ROE—
ROA-220.6%
ROIC (approx.)—
Asset turnover2.06x

Leverage & solvency

Liabilities / assets636.4%
Debt / equity—
Current ratio0.27x
Interest coverage-5.12x

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-66.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-07-31FY20252025-07-31
Income statement
Revenue$2.31M$2.20M
Cost of revenue$992,000$899,000
Gross profit$1.33M$1.30M
R&D expense$332,000$316,000
SG&A expense$3.08M$3.26M
Operating income-$2.08M-$2.27M
Interest expense$407,000$299,000
Income tax$0$0
Net income-$2.48M-$2.40M
EBITDA-$2.08M-$2.27M
EPS (basic)-0.02-0.02
EPS (diluted)-0.02-0.02
Weighted avg. shares (diluted)116.46M111.86M
Balance sheet
Cash & equivalents$569,000$334,000
Receivables$334,000$474,000
Inventory$193,000$141,000
Current assets$1.19M$1.05M
PP&E, net$8,000$11,000
Total assets$1.19M$1.06M
Current liabilities$4.37M$2.11M
Long-term debt$6.60M—
Total debt$6.60M—
Total liabilities$7.59M$6.17M
Shareholders' equity-$6.40M-$5.12M
Net debt$6.03M—
Shares outstanding130.02M111.89M
Cash flow statement
Operating cash flow-$1.74M-$2.02M
Financing cash flow$1.97M$2.00M
Depreciation & amortization$3,000$2,000
Stock-based compensation$197,000$147,000

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.